HC Wainwright Estimates Alector FY2030 Earnings

Alector, Inc. (NASDAQ:ALEC) – Analysts at HC Wainwright issued their FY2030 earnings estimates for Alector in a report issued on Friday, February 27th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.58) for the year. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%. The firm had revenue of $6.24 million for the quarter, compared to analysts’ expectations of $1.78 million.

ALEC has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research note on Wednesday, January 21st. Morgan Stanley reiterated an “underweight” rating on shares of Alector in a research report on Thursday, January 8th. Wall Street Zen downgraded shares of Alector from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, BTIG Research upgraded shares of Alector from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.25.

Alector Trading Down 5.1%

NASDAQ:ALEC opened at $2.43 on Monday. Alector has a 12 month low of $0.87 and a 12 month high of $3.40. The company has a current ratio of 3.83, a quick ratio of 3.83 and a debt-to-equity ratio of 0.30. The firm’s 50 day moving average is $1.85 and its 200 day moving average is $2.03. The stock has a market capitalization of $268.17 million, a PE ratio of -1.75 and a beta of 0.57.

Insiders Place Their Bets

In other Alector news, insider Sara Kenkare-Mitra sold 41,687 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $46,689.44. Following the sale, the insider owned 501,652 shares of the company’s stock, valued at $561,850.24. This trade represents a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Neil Lindsay Berkley sold 37,261 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total transaction of $41,732.32. Following the completion of the transaction, the chief financial officer owned 374,309 shares in the company, valued at approximately $419,226.08. This trade represents a 9.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 200,183 shares of company stock worth $230,262 in the last ninety days. 9.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alector

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in shares of Alector by 1.8% during the second quarter. Bank of America Corp DE now owns 343,909 shares of the company’s stock valued at $481,000 after purchasing an additional 5,927 shares during the period. Los Angeles Capital Management LLC grew its holdings in Alector by 5.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company’s stock worth $213,000 after acquiring an additional 7,600 shares during the last quarter. Sio Capital Management LLC grew its holdings in Alector by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 845,531 shares of the company’s stock worth $1,184,000 after acquiring an additional 8,372 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Alector by 3.4% in the third quarter. Mackenzie Financial Corp now owns 283,712 shares of the company’s stock valued at $840,000 after acquiring an additional 9,270 shares during the period. Finally, Lexington Partners L.P. bought a new position in shares of Alector during the third quarter valued at about $30,000. 85.83% of the stock is currently owned by institutional investors.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.